Results 111 to 120 of about 2,198,265 (159)

ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis. [PDF]

Cardiol Ther
Pfister R, Michel L, Schulze M, Vogtländer K, Ciaccia A, Merz M, Hengstenberg C.   +6 more
europepmc   +1 more source

Visual scoring of bone scintigraphy in ATTR-CM: insights from the TTRACK study. [PDF]

ESC Heart Fail
Tingen HSA, Gorter TM, Slart RHJA.
europepmc   +1 more source

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy [PDF]

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and ...
Walsh, Liron, Olbertz, Joy, Täubel, Jörg, Gane, Edward J, Razvi, Yousuf, Rocha, Ricardo, Zhu, Peijuan, Gillmore, Julian D, Lebwohl, David, Gutstein, David E, Smith, Derek, Haagensen, Alexandra, Xu, Yuanxin, Sonderfan, Alison, Adams, David, Kachadourian, Jessica, Solomon, Scott D, Fontana, Marianna, Leung, Adia, Pilebro, Björn   +19 more
core  

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study. [PDF]

Future Cardiol
Masri A, Judge DP, Ruberg FL, Gillmore JD, Grodin JL, Obici L, Maurer MS, Fontana M, Poulsen SH, van der Meer P, Cheng RK, Cuddy SAM, Ambardekar AV, Xiong K, Cao X, Murtagh G, Siddhanti S, Castaño A, Tamby JF, Fox JC, Alexander KM, Witteles R.   +21 more
europepmc   +1 more source

Wild-type transthyretin amyloidosis (ATTR-wt): preliminary study on the prevalence of peripheral neuropathy in patients with ATTR-wt cardiomyopathy

reservedIntroduzione: L’amiloidosi da transtiretina wild type (ATTR-wt) è una patologia sistemica progressiva acquisita, che interessa prevalentemente i soggetti anziani di sesso maschile. La manifestazione primaria della patologia è lo sviluppo di una
RAMPOGNA, MATILDE
core  

Efficacy of tafamidis across age groups in ATTR-CM: insights from real-world data. [PDF]

Cardiol J
Gregório C, Agostinho JR, Abrantes A, Vilela M, Batista M, Abrantes F, Garcia AB, Campos C, Conceição I, Pinto FJ, Brito D.   +10 more
europepmc   +1 more source

<i>In-vivo</i> CRISPR editing for ATTR-CM: therapeutic transthyretin silencing through hepatic genome correction. [PDF]

Ann Med Surg (Lond)
Tahir A, Imtiaz E, Ali FZ, Khan MS, Mahato RK.   +4 more
europepmc   +1 more source

Real-World Efficacy of Tafamidis in Korean ATTR-CM Patients: A Retrospective Observational Strain Analysis. [PDF]

Korean Circ J
Shin H, Jeon K, Kim D, Hong D, Park M, Yoon SE, Kim SJ, Kim JS, Kim K, Choi JO.   +9 more
europepmc   +1 more source

Functionally Limiting Symptoms and Inability to Independently Complete Daily Activities Increase the Burden Felt by Caregivers to Patients with ATTR-CM. [PDF]

Cardiol Ther
Cappelli F, Ponti L, Smorti M, Hsu K, Damy T, Verheyen N, Wang R, Kumar N, Munteanu C, Burden of Disease Study Investigators.   +9 more
europepmc   +1 more source

Tc-99 m Pyrophosphate Uptake in Atrial Amyloidosis With Hemorrhagic Mass　- A Diagnostic Pitfall Mimicking ATTR-CM. [PDF]

Circ Rep
Fujimoto N, Moriwaki K, Makino M, Dohi K.   +3 more
europepmc   +1 more source